Experimental Models of Transcription Factor-Associated Maturity-Onset Diabetes of the Young

  1. Haiyan Wang1,
  2. Kerstin Hagenfeldt-Johansson1,
  3. Luc A. Otten2,
  4. Benoit R. Gauthier1,
  5. Pedro L. Herrera3 and
  6. Claes B. Wollheim1
  1. 1Department of Internal Medicine, Division of Clinical Biochemistry, University Medical Centre, Geneva, Switzerland
  2. 2Biochemistry Institute, University of Lausanne, Lausanne, Switzerland
  3. 3Department of Morphology, University Medical Centre, Geneva, Switzerland

    Abstract

    Six monogenic forms of maturity-onset diabetes of the young (MODY) have been identified to date. Except for MODY2 (glucokinase), all other MODY subtypes have been linked to transcription factors. We have established a MODY3 transgenic model through the β-cell–targeted expression of dominant-negative HNF-1α either constitutively (rat insulin II promoter) or conditionally (Tet-On system). The animals display either overt diabetes or glucose intolerance. Decreased insulin secretion and reduced pancreatic insulin content contribute to the hyperglycemic state. The conditional approach in INS-1 cells helped to define new molecular targets of hepatocyte nuclear factor (HNF)-1α. In the cellular system, nutrient-induced insulin secretion was abolished because of impaired glucose metabolism. Conditional suppression of HNF-4α, the MODY1 gene, showed a similar phenotype in INS-1 cells to HNF-1α. The existence of a regulatory circuit between HNF-4α and HNF-1α is confirmed in these cell models. The MODY4 gene, IPF-1 (insulin promoter factor-1)/PDX-1 (pancreas duodenum homeobox-1), controls not only the transcription of insulin but also expression of enzymes involved in its processing. Suppression of Pdx-1 function in INS-1 cells does not alter glucose metabolism but rather inhibits insulin release by impairing steps distal to the generation of mitochondrial coupling factors. The presented experimental models are important tools for the elucidation of the β-cell pathogenesis in MODY syndromes.

    Footnotes

    • Address correspondence and reprint requests to Claes Wollheim, Division of Clinical Biochemistry, Department of Internal Medicine, University Medical Centre, CH-1211 Geneva 4, Switzerland. E-mail: claes.wollheim{at}medecine.unige.ch.

      Received for publication 20 March 2002 and accepted in revised form 16 April 2002.

      H.W. and K.H.-J. contributed equally to this work.

      DN, dominant negative; Dtr, double transgenic; HNF, hepatocyte nuclear factor; KATP channel, ATP-sensitive K+ channel; L-PK, liver-type pyruvate kinase; MODY, maturity-onset diabetes of the young; OGDH, 2-oxoglutarate dehydrogenase; PDX-1, pancreas duodenum homeobox-1; RIP, rat insulin promoter; rtTA, reverse tetracycline-dependent transactivator; TCA, tricarboxylic acid; UCP, uncoupling protein.

      The symposium and the publication of this article have been made possible by an unrestricted educational grant from Servier, Paris.

    « Previous | Next Article »Table of Contents